Main content

CSL Bioplasma Products

Major plasma products marketed by CSL Bioplasma

Haemophilia and Other
Coagulation Disorders

Coagulation therapies are used to treat bleeding disorders such as haemophilia and von Willebrand disease.

  • Biostate®
    (human coagulation factor VIII/von Willbrand Factor concentrate)
  • MonoFix® -VF
    (human coagulation factor IX)
  • Prothrombinex® -VF
    (human prothromin factor)
Diagnostic Products

Diagnostic products are used in the testing of blood to prevent haemolytic transfusion reactions and haemolytic disease of the foetus and newborn, and for snake venom detection.

  • Reagent Red Blood Cells
  • Monoclonal Reagents
  • Supplementary Reagents
  • Snake Venom Detection Products
    Used to detect venom in snakebite victims and indicate the appropriate monovalent antivenom for treatment.
Critical Care Conditions

Critical care products are used in fluid resuscitation, for replacement of albumin, and to treat specific factor deficiencies.

  • Albumex®
    (human albumin)
  • Thrombotrol® -VF
    (human antithrombin III)
Immune Disorders and
Immune Therapy

Immunoglobulins are used to treat immunodeficiency, modify the function of the immune system, and for protection against specific infections.

  • Intragam® P
    (6g liquid intravenous immunoglobulin)
  • Normal Immunoglobulin-VF
    (human normal immunoglobulin)
  • Rh(D) Immunoglobulin-VF
    (human Rh (D) immunoglobulin)
  • CMV Immunoglobulin-VF
    (human cytomegalovirus immunoglobulin)
  • Hepatitis B Immunoglobulin-VF
    (human hepatitis B immunoglobulin)
  • Zoster Immunoglobulin-VF
    (human zoster immunoglobulin)
  • Tetanus Immunoglobulin-VF
    (human tetanus immunoglobulin)

Special Access Scheme
Under Australia’s Special Access Scheme, CSL Bioplasma distributes several life-saving, plasma-derived products for the treatment of rare conditions.

Sandoglobulin® NF Liquid
(12% liquid intravenous immunoglobulin) manufactured by CSL Behring and distributed in Australia by CSL Bioplasma.

Toll Fractionation
CSL Bioplasma performs plasma fractionation for Australia’s National Blood Authority, a role pivotal to Australia’s policy of self-sufficiency. CSL Bioplasma is also the national fractionator of New Zealand, Hong Kong, Malaysia and Singapore.